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Abstract Heart failure is a life-threatening disease with
a growing incidence in the Netherlands. This growing in-
cidence is related to increased life expectancy, improve-
ment of survival after myocardial infarction and better treat-
ment options for heart failure. As a consequence, the
costs related to heart failure care will increase. Despite
huge improvements in treatment, the prognosis remains
unfavourable with high one-year mortality rates. The in-
troduction of implantable devices such as implantable car-
dioverter defibrillators (ICD) and cardiac resynchronisation
therapy (CRT) has improved the overall survival of patients
with chronic heart failure. However, after ICD implan-
tation for primary prevention in heart failure a high per-
centage of patients never have appropriate ICD discharges.
In addition 25–50 % of CRT patients have no therapeu-
tic effect. Moreover, both ICDs and CRTs are associ-
ated with malfunction and complications (e. g. inappro-
priate shocks, infection). Last but not least is the rela-
tively high cost of these devices. Therefore, it is essential,
not only from a clinical but also from a socioeconomic
point of view, to optimise the current selection criteria for
ICD and CRT. This review focusses on the role of car-
diac sympathetic hyperactivity in optimising ICD selection
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criteria. Cardiac sympathetic hyperactivity is related to fa-
tal arrhythmias and can be non-invasively assessed with
123I-meta-iodobenzylguanide (123I-mIBG) scintigraphy. We
conclude that cardiac sympathetic activity assessed with
123I-mIBG scintigraphy is a promising tool to better iden-
tify patients who will benefit from ICD implantation.
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Introduction
Heart failure (HF) is a life-threatening disease affecting
approximately 26 million people worldwide [1]. The inci-
dence of HF in the Netherlands ranges between 28,000 and
44,000 cases per year and increases with age; the majority
of HF patients are older than 75 years [2]. Currently, there
are between 100,000 and 150,000 patients with HF in the
Netherlands. It is the only cardiovascular disease with both
growing incidence and prevalence [3]. Reasons for this
trend are related to increased life expectancy, improvement
of survival after myocardial infarction and better treatment
options for HF (Fig. 1). It is expected that the total number
of HF patients in the Netherlands will increase to 275,000
in 2040 [4]. As a consequence, the costs related to HF care
will increase: in 2007 these costs were 455 million euro
which rose to 940 million in 2011 [2, 5]. For 2025, these
costs are estimated at 10 billion euros [4].
Despite the successful introduction of treatment with
a combination of beta-blockers and angiotensin-converting-
enzyme inhibitors or angiotensin receptor blockers together
with loop diuretics, the prognosis of chronic HF (CHF) re-
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Fig. 1 Number of deaths as
a result of acute myocardial
infarction and heart failure in
the Netherlands from 1980 to
2010. The decrease in the num-
ber of deaths after myocardial
infarction declines more rapidly
than the increase in the number
of deaths due to heart failure.
Source: Centraal Bureau voor
de Statistiek (CBS), the Nether-
lands
mains unfavourable. The most recent European data (ESC-
HF pilot study) demonstrate that 12-month all-cause mortal-
ity rates for hospitalised and stable/ambulatory HF patients
were 17 and 7%, respectively [6]. The majority of these
deaths are caused by progression of HF, lethal arrhythmia
and sudden cardiac death. The use of implantable devices
such as implantable cardioverter defibrillators (ICD) and
cardiac resynchronisation therapy (CRT) has improved the
overall survival of CHF patients [7–10]. Current European
guidelines recommend ICD for primary prevention of fa-
tal arrhythmias in CHF subjects with an ejection fraction
<35% and symptomatic HF NYHA class ≥2 under opti-
mal pharmacological therapy [11]. In addition, CRT is
recommended in CHF patients who remain symptomatic
in NYHA class ≥2 under optimal pharmacological therapy,
with a left ventricular ejection fraction (LVEF) <35% and
wide QRS complex (≥130 ms).
ICDs applied for primary or secondary (i.e. already
proven ventricular arrhythmias) prevention reduce the rela-
tive risk of death by 20 %. However, analysis of the MA-
DIT II (Second Multicenter Automated Defibrillator Im-
plantation Trial) has shown that the absolute reduction of
fatal events was only 5.6 % (19.8 to 14.2 %) [8]. In addi-
tion, the SCD-HeFT (Sudden Cardiac Death in Heart Fail-
ure Trial) study showed that the annual number of ICD
shocks was 7.1 % of which 5.1 % were appropriate in the
first year rising to 21 % in the 5th year post-implantation
[12]. However, three years after ICD implantation for pri-
mary prevention, a remarkably high percentage of 65 % had
never received appropriate ICD therapy. Moreover, there is
also a risk of malfunction and operative complications, e.g.
inappropriate shocks, infection.
Although the indications for CRT are well established,
between one-quarter and one-half of patients who receive
a CRT device are reported to show no response to the inter-
vention. The MIRACLE (Multicenter InSync Randomized
Clinical Evaluation) trial showed no therapeutic effect in
33 % of patients using a clinical composite score [13].
Last but not least is the relative high cost of these devices.
Therefore, it is essential, not only from a clinical but also
from a socioeconomic point of view, to optimise the current
selection criteria for CRT and ICD for primary prevention
aimed at better identification of patients who will benefit
from implantation.
Currently one of the selection criteria for CRT and ICD
implantation for primary prevention is an LVEF <35%.
However LVEF assessed by cardiovascular magnetic reso-
nance imaging (CMR) is significantly lower compared with
echocardiography [14]. Therefore CMR would significantly
increase the number of CHF patients eligible for CRT or
ICD implantation. This illustrates that the method to assess
LVEF has substantial impact on the selection of ‘appro-
priate’ patients for CRT and ICD implantation. The lack
of uniformity among imaging modalities to assess LVEF
raises the question if other parameters may be useful to
better identify those patients who will benefit from CRT
or ICD implantation. One of those alternative parameters
might be cardiac sympathetic hyperactivity, which is related
to poor prognosis and fatal arrhythmias in CHF. Cardiac
sympathetic activity can be non-invasively assessed with
cardiac 123I-meta-iodobenzylguanide (123I-mIBG) scintigra-
phy. Scholtens et al. described in a relatively recent review
the possible role of 123I-mIBG to better select CRT candi-
dates [15]. Therefore the role of 123I-mIBG to better select
CRT candidates will only be briefly discussed in this review.
This review has three interrelated aims: First, to describe
the pathophysiology of the cardiac sympathetic nervous
system in HF. Secondly, how cardiac sympathetic activ-
ity can be non-invasively assessed with cardiac 123I-mIBG
scintigraphy and thirdly to critically assess the available
literature regarding cardiac 123I-mIBG scintigraphy in the
specific context of ICD.
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Cardiac sympathetic activity
Norepinephrine is the neurotransmitter of the cardiac sym-
pathetic system and is stored in vesicles in the presynap-
tic nerve terminals (Fig. 2). On the basis of tissue nor-
epinephrine content, the heart is characterised by dense
sympathetic innervation with a gradient from atria to base
of the heart and from base to apex of the ventricles [16].
Via exocytosis, norepinephrine is released into the synaptic
cleft. Only a small amount of the released norepinephrine in
the synaptic cleft is available to stimulate the post-synaptic
β-adrenergic receptors (β-AR) on the myocytes. Most of the
norepinephrine undergoes reuptake into the nerve terminals
via the uptake-1 mechanism. This transport system, i. e.
norepinephrine transporter (NET), is sodium and chloride
dependent and responsible for approximately 70–90 % of
the norepinephrine re-uptake from the myocardial synaptic
cleft.
Fig. 2 Schematic representation of the sympathetic synapse. Nor-
epinephrine is synthesised within neurons by an enzymatic cascade.
Dihydroxyphenylalanine (DOPA) is generated from tyrosine and sub-
sequently converted to dopamine by DOPA decarboxylase. Dopamine
is transported into storage vesicles by the energy-requiring vesicular
monoamine transporter (VMAT). Norepinephrine is synthesised by
dopamine β-hydroxylase within these vesicles. Neuronal stimula-
tion leads to norepinephrine release through fusion of vesicles with
the neuronal membrane (exocytosis). Apart from neuronal stimula-
tion, release is also regulated by a number of presynaptic receptor
systems, including α2-adrenergic receptors, which provide negative
feedback for exocytosis. Most norepinephrine undergoes reuptake into
nerve terminals by the presynaptic norepinephrine transporter (NET)
and is re-stored in vesicles (following uptake by vesicular amine trans-
porter 2 (VMAT2)) or is metabolised in cytosol dihydroxyphenylglycol
(DHPG) by monoamine oxidase (MAO)
The cardiac sympathetic system is one of the neurohor-
monal compensation mechanisms that plays an important
role in the pathogenesis of CHF with impaired LVEF.
Patients with CHF have increased cardiac sympathetic ac-
tivity with increased exocytosis of norepinephrine from
the presynaptic vesicles. In addition, the norepinephrine
re-uptake via the NET in the sympathetic terminal nerve
axons is decreased resulting in elevated synaptic levels
of norepinephrine. Eventually this results in increased
plasma and urinary levels of norepinephrine concomitant
with the severity of left ventricular dysfunction [17–19].
Initially, β-AR stimulation by increased norepinephrine
levels helps to compensate for impaired myocardial func-
tion, but long-term norepinephrine excess has detrimental
effects on myocardial structure and gives rise to a down-
regulation and decrease in the sensitivity of post-synaptic
β-AR [20, 21]. This downregulation leads to left ventricu-
lar remodelling and is associated with increased mortality
and morbidity. Increased norepinephrine plasma levels are
associated with poor prognosis in CHF [18]. However,
these levels do not specifically reflect the sympathetic ac-
tivity at a cardiac level. In addition, these measurements
are time consuming and there is a high variability in mea-
surements. However, cardiac sympathetic activity can be
non-invasively visualised by nuclear techniques. To date,
most commonly used tracers are norepinephrine analogues
(123I-mIBG) for single photon emission tomography (SPECT)
and 11C-hydroxyephedrine for positron emission tomogra-
phy (PET). Both radiotracers are resistant to metabolic
enzymes and show high affinity for presynaptic nor-
epinephrine uptake-1 (NET) allowing the visualisation of
presynaptic sympathetic nerve function. Other presynaptic
PET tracers include 11C-epinephrine, 11C-phenylephrine,
and 18F-LMI1195. 11C-CGP12177 is the most commonly
used tracer for postsynaptic β-ARs [22–24]. However,
unlike 123I-mIBG, which can be centrally manufactured
and then distributed, most PET agents are labelled with
short half-life isotopes and are therefore only available in
institutions with an on-site cyclotron. Although the early
development of an 18F-labelled compound for sympathetic
PET imaging is continuing [25], for the foreseeable fu-
ture 123I-mIBG scintigraphy will remain the only widely
available nuclear imaging method for assessing global and
regional myocardial sympathetic innervation. In addition,
cardiac 123I-mIBG scintigraphy is easily implemented in
any department of nuclear medicine and thereby readily
available for CHF patients.
123I-mIBG scintigraphy
123I-mIBG is a norepinephrine analogue that shares the same
presynaptic uptake, storage and release mechanism as nor-
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epinephrine. Because 123I-mIBG is not metabolised, its ac-
cumulation over several hours is a measure of neuronal
sympathetic integrity of the myocardium. Since the in-
troduction of cardiac 123I-mIBG scintigraphy, parameters of
123I-mIBG myocardial uptake and washout have been shown
to be of clinical value in many cardiac diseases, especially
for the assessment of prognosis [26–29]. Cardiac 123I-mIBG
scintigraphy has been established as a highly reproducible
and feasible technique to evaluate the global and regional
cardiac sympathetic function [30, 31].
123I-mIBG scintigraphy planar acquisition and analysis
To block uptake of free 123I by the thyroid gland, subjects
are pretreated with 250 mg of oral potassium iodide 30 min
before intravenous injection of 185 MBq 123I-mIBG. Fif-
teen minutes (early acquisition) and 4 h (late acquisition)
after administration of 123I-mIBG, 10-min planar images
are acquired with the subjects in a supine position us-
ing a gamma camera equipped with a low energy high
resolution or medium collimator. Based on the obtained
planar (2D) images, three major outcomes of myocardial
123I-mIBG uptake can be determined: the early and late
heart/mediastinal (H/M) ratio and cardiac washout rate
(WO). The H/M ratio is calculated from planar 123I-mIBG
images using a regions-of-interest (ROI) over the heart
(Fig. 3). Standardised background correction is derived
from a fixed rectangular mediastinal ROI placed on the
upper part of the mediastinum [32]. The location of the
mediastinal ROI is determined in relation to the lung apex,
Fig. 3 Two examples of planar cardiac 123I-mIBG scintigraphy using
a medium collimator with different late (4h p.i.) myocardial 123I-mIBG
uptake in subjects with the same LVEF compared with a healthy sub-
ject. a 63-year-old patient with ischaemic heart failure. b 68-year-old
patient with ischaemic heart failure. c 32-year-old healthy person.
d Example of placing a region-of-interest (ROI) over the heart (H) and
fixed rectangular mediastinal ROI placed on the upper part of the me-
diastinum (M) for calculating H/M ratio
the lower boundary of the upper mediastinum, and the mid-
line between the lungs. The H/M ratio is calculated by di-
viding the mean count density in the cardiac ROI by the
mean count density in the mediastinal ROI [32]. The 123I-
mIBG WO can be calculated using early and late H/M ra-
tio (1). There are variations to the WO calculation using
the myocardial count densities only, requiring a time-decay
correction (factor of 1.21), without (2) or with background
correction (3):
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The early H/M ratio predominantly reflects the integrity
of sympathetic nerve terminals (i. e. number of functioning
nerve terminals and intact uptake-1 mechanism). The late
H/M ratio particularly offers information about neuronal
function resulting from uptake, storage and release. The
123I-mIBG WO reflects predominantly neuronal integrity of
sympathetic tone/adrenergic drive [33].
123I-mIBG scintigraphy SPECT acquisition and analysis
Further, compared with the H/M ratio derived from two-di-
mensional planar images, the results of three-dimensional
imaging using SPECT provide a more complete understand-
ing of global dysinnervation [34, 35]. Preclinical and an-
imal studies suggested that myocardial regions with dam-
aged or dysfunctional neurons but preserved perfusion can
be a source of arrhythmias. Therefore, volumetric data such
as SPECT may be of added value. The specific SPECT
acquisition parameters have been described elsewhere but
are largely comparable with those used for myocardial per-
fusion SPECT imaging [32]. Images can be processed
and prepared for display and interpretation using the avail-
able commercial software packages (e. g. Emory Cardiac
Toolbox and Cedar-Sinai Quantitative Perfusion SPECT).
While there is no officially established method for scoring
123I-mIBG SPECT images, analysis can be performed sim-
ilar to the conventional 17-segment/5-point model used for
SPECT myocardial perfusion imaging (MPI) (Fig. 4; [36]).
Therefore the 123I-mIBG SPECT images can easily be com-
pared with MPI SPECT images in order to investigate the
difference between regional innervation and possible my-
ocardial perfusion abnormalities [37, 38].
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Fig. 4 Example of late
123I-mIBG SPECT imaging. On
the left the conventional short,
vertical and horizontal axis, in
the middle the corresponding
17-segment model polar map
and on the right a 3D recon-
struction. There is impaired
regional 123I-mIBG uptake in
the inferior wall from the my-
ocardial base until the apex with
extension to both inferoseptal
and inferolateral regions
Planar 123I-mIBG as predictor of cardiac morbidity and
mortality in CHF
Cardiac sympathetic hyperactivity is reflected by a de-
creased 123I-mIBG late H/M ratio and increased WO. Both
are associated with increased fatal arrhythmia and cardiac
mortality. It has been reported that late H/M ratio < 1.6 is
associated with poor outcome [29]. However, meta-analy-
ses showed that in patients with CHF, late H/M ratio is not
only useful as a dichotomous predictor of events (high vs.
low risk), but also has prognostic implication over the full
range of the outcome value for all event categories except
arrhythmias [39]. Although a WO cut-off value of 27 has
been reported, it is important to realise that several other
WO cut-off values have been reported [40]. Therefore there
is no consensus on the exact WO cut-off value.
Initially 123I-mIBG scintigraphy assessed cardiac sym-
pathetic activity in CHF has extensively been studied in
small, single-centre studies. However the ADMIRE-HF
study (ADreView Myocardial Imaging for Risk Evaluation
in Heart Failure), a large multicentre, prospective study, re-
ported that decreased late H/M ratio was associated with the
composite endpoint of HF progression, ventricular tachy-
arrhythmia and death [29]. A total of 961 CHF patients
with NYHA functional class II/III and a LVEF <35 %
were enrolled. In this study, a predefined late H/M ra-
tio cut-off value of 1.6 was used. Late H/M ratio was
independent of brain natriuretic peptide and LVEF, as
a predictor of the composite endpoint as well as of each
individual component of the composite endpoint: pro-
gression of HF, lethal ventricular arrhythmia and sudden
cardiac death. A late H/M ratio > 1.6 was associated
with 1 % of cardiac deaths per year. In contrast, the an-
nual cardiac mortality in a cohort with late H/M ratio <
1.2 was almost 10 times higher (9.6 %). In a re-analy-
sis of the ADMIRE-HF data in 778 patients without an
ICD at the start of the study, the predictive value of H/M
ratio on ventricular tachyarrhythmia was analysed [41].
A late H/M ratio < 1.6 was associated with a 3.5-fold
increased probability of an arrhythmia (hazard ratio [HR]
3.48, 95 % CI 1.52 to 8). This association was independent
of other clinical predictors of ventricular tachyarrhythmia
including LVEF. Therefore, it is tempting to speculate that
123I-mIBG scintigraphy may have a role in the management
of HF patients. Indeed a prediction model for 5-year car-
diac mortality in patients with HF using 123I-mIBG has been
developed [42]. The formula for predicting 5-year mortality
was created using a logistic regression model. By including
the late H/M ratio in the model, the net reclassification im-
provement analysis for all subjects was 13.8 % (p < 0.0001).
The inclusion of the late H/M ratio was most effective in
the down reclassification of low-risk patients. To illustrate
the independent prognostic role of myocardial 123I-mIBG
scintigraphy some examples are given in Fig. 3.
123I-mIBG SPECT as predictor of cardiac morbidity and
mortality in CHF
There is evidence that regional innervation/perfusion mis-
match predispose to arrhythmias [43, 44]. Inhomogeneity
in myocardial sympathetic innervation may create a my-
ocardial substrate particularly vulnerable to arrhythmic
death. This inhomogeneity can reflect sympathetic den-
ervation from infarction, as well as reversible ischaemia.
123I-mIBG SPECT and 123I-mIBG/99mTc-tetrofosmin SPECT
mismatch was shown to be a predictor of appropriate ICD
therapy [45, 46]. In 27 CHF patients with ICD for primary
prevention 123I-mIBG SPECT and the 123I-mIBG/99mTc-
tetrofosmin SPECT mismatch were independent predictors
of arrhythmic events [45]. In a larger prospective study
in 116 CHF patients, eligible for ICD implantation for
both primary and secondary prevention of sudden cardiac
death, SPECT was shown to be an independent predictor
of appropriate ICD therapy and cardiac death [38]. The
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cumulative incidence of appropriate ICD therapy during
3 years of follow-up was significantly higher with a rel-
atively large 123I-mIBG SPECT defect (median summed
score ≥26). More recently, 123I-mIBG SPECT assessed
cardiac sympathetic activity and 99mTc-tetrofosmin assessed
perfusion were studied as predictors of arrhythmic events
in 471 patients with ischaemic CHF [47]. Multivariate pro-
portional hazards analysis showed 123I-mIBG SPECT was
an independent predictor of arrhythmic events (HR: 0.975,
p = 0.042). In addition the authors concluded that the pre-
sumption of a monotonic increase in risk of an arrhythmic
event with increasing 123I-mIBG SPECT defects may not
be correct. This conclusion was based on the observation
that in ischaemic CHF patients, those with intermediate de-
fects appeared to be at the highest risk. A recent prospec-
tive PET study showed that 11C-hydroxyephedrine assessed
sympathetic activity in ischaemic heart disease (n = 204),
predicted cause-specific mortality from sudden cardiac ar-
rest independently of LVEF and infarct volume [48]. These
findings may be useful to better identify patients who, most
likely, benefit from ICD implantation.
Recently the use of a computer quantitation method for
myocardial 123I-mIBG SPECT studies was introduced [49].
In this study the incremental prognostic significance of
123I-mIBG SPECT imaging on all-cause and cardiac mortal-
ity for subjects (n = 938) in the ADMIRE-HFX study was
assessed. The interactions between regional cardiac sympa-
thetic activity (123I-mIBG SPECT) and abnormal perfusion
(99mTc-tetrofosmin SPECT) were explored. The highest car-
diac mortality risk for ischaemic HF subjects (n = 619) was
seen with perfusion defects involving 20–40 % of the my-
ocardium. By comparison, non-ischaemic HF subjects (n =
319) with smaller perfusion abnormalities (<20 % of my-
ocardium), but with a large discrepancy between 123I-mIBG
and 99mTc-tetrofosmin defect sizes, were at highest risk of
cardiac death. The authors concluded that automated de-
rived 123I-mIBG SPECT in combination with 99mTc-tetrofos-
min SPECT scores can effectively be used in the assessment
of the prognosis of patients with HF.
123I-mIBG as predictor of CRT response
CRT has been shown to reduce mortality and morbidity due
to reverse remodelling. The review by Scholtens et al., in-
cluding nine studies with a total number of 225 patients,
focused on CRT and cardiac innervation scintigraphy with
123I-mIBG. First and foremost there was a lack of uniform
response criteria for CRT [15]. Nevertheless, in all available
studies, 123I-mIBG showed positive changes in cardiac sym-
pathetic nerve activity in responders to CRT. Additionally,
123I-mIBG imaging proved to be promising in identifying
patients who did not benefit from CRT, alone or as part of
an algorithm in combination with other parameters. How-
ever, studies are relatively small and extrapolation of these
findings is hampered by the lack of uniform response cri-
teria. Therefore, larger studies with uniform CRT response
criteria are needed to confirm these provisional data.
Need for standardisation
Although planar 123I-mIBG scintigraphy is a highly repro-
ducible technique to assess cardiac sympathetic activity and
has a small inter- and intra-observer variation [30], stand-
ardisation of acquisition and analysis is needed. The lack
of standardisation between different institutions is one of
the factors that have hampered the wide scale clinical im-
plementation of cardiac 123I-mIBG scintigraphy. Some se-
rious international efforts have been made to harmonise
and standardise cardiac 123I-mIBG scintigraphy [32]. These
recommendations include proposals for patient preparation,
administered amounts of 123I-mIBG activity (MBq), scan-
ning parameters (e. g. choice of collimators), and analysis
of the acquired data to obtain the most used semi-quanti-
tative parameters (i. e. early and late H/M ratio and 123I-
mIBG WO). To further the role of 123I-mIBG scintigraphy
in CHF, a strict use of these recommendations is essential
to compare data from different institutions.
Incorporating 123I-mIBG scintigraphy into the assessment
of CHF patients eligible for ICD implantation was associ-
ated with a reduction in ICD utilisation of 21 % [50]. Con-
sequently, the number needed to screen to prevent one ICD
implantation is 5. Screening with 123I-mIBG scintigraphy
will reduce the costs per patient by 5500 and 13,431 US
dollars over 2 and 10 years, respectively. In comparison, no
screening with 123I-mIBG scintigraphy results in losses of
0.001 and 0.040 life-years over 2 and 10 years, respectively.
Conclusion
In conclusion, HF is a widespread disease with rapidly in-
creasing prevalence and is characterised by increased car-
diac sympathetic activity. This hyperactivity is related to
the progression of HF, fatal ventricular tachyarrhythmia
and mortality. Non-invasive assessment of cardiac sympa-
thetic activity with 123I-mIBG scintigraphy with standard-
ised quantification techniques enables better identification
of HF patients who will benefit from ICD implantation to
improve their prognosis. Better selection of the CHF pa-
tient who will benefit from expensive HF therapy (i. e. CRT
or ICD) will help to constrain the HF related costs.
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